Form 4: Celldex Therapeutics SVP Sarah Cavanaugh Granted 78,000 Stock Options

Celldex Therapeutics' Senior Vice President of Corporate Affairs & Administration, Sarah Cavanaugh, was granted 78,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Sarah Cavanaugh, SVP of Corporate Affairs & Administration at Celldex Therapeutics, Inc. (CLDX), was granted 78,000 incentive stock options.
• The transaction date for this grant was June 5, 2025.
• Each option has an exercise price of $19.53.
• The options were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• The vesting schedule for these options is 25% on June 5, 2026, with the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Sarah Cavanaugh beneficially owns 78,000 derivative securities (incentive stock options) directly.

Sentiment

Score: 7

Explanation: The grant of incentive stock options to a senior executive is a positive development as it aligns management's long-term interests with those of shareholders, encouraging performance and retention. While routine, it signals continued commitment to executive incentives.

Positives

• The grant of incentive stock options to a senior executive aligns management's long-term interests with those of shareholders, encouraging performance and retention.
• The options are part of a structured equity incentive plan, indicating a commitment to long-term value creation.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Celldex Therapeutics' common stock, which is subject to market volatility and company performance.
• The options are subject to a vesting schedule, meaning the executive must remain with the company for the options to become fully exercisable.

Future Outlook

This filing indicates future equity compensation for a key executive, with options vesting over the next four years, aligning her long-term financial interests with the company's performance.

Industry Context

The granting of incentive stock options is a common and standard practice in the biotechnology and pharmaceutical industries for executive compensation, serving as a long-term incentive to retain talent and align management's interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to senior executives is a prevalent compensation strategy across the biotech industry, similar to practices observed at companies like Regeneron Pharmaceuticals or Vertex Pharmaceuticals, aiming to incentivize long-term performance.
• The vesting schedule of 25% after one year and quarterly thereafter over three years is a typical structure for long-term incentive plans in the sector, providing a balance between immediate reward and sustained commitment, comparable to plans at companies such as Gilead Sciences or Amgen.

Corporate Governance

Related Party Transactions

• The grant of incentive stock options to Sarah Cavanaugh, a Senior Vice President, constitutes a related party transaction as it involves compensation provided by the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized executive performance and alignment of interests.
• Employees (specifically Sarah Cavanaugh): Direct financial benefit and long-term incentive tied to company performance and continued employment.

Next Steps

• The options will begin to vest on June 5, 2026, with subsequent vesting occurring quarterly over the following three years.
• The executive may choose to exercise the vested options at any time before their expiration date of June 5, 2035, subject to company policy and market conditions.

Key Dates

Recommendation

Keywords

Celldex Therapeutics, CLDX, Stock Options, Incentive Stock Option, Form 4, Insider Transaction, Equity Compensation, Sarah Cavanaugh, Executive Compensation, Vesting Schedule